AMANDA OSWALT: Open Payments
NPI 1710175815 · WASHINGTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,801 in 19 payments from 9 companies in 2025. Trend: 2023 $493 · 2024 $319 · 2025 $2,801
Honoraria: $1,625Travel & lodging: $911Food & beverage: $265
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 7 | $2,581 |
| Lilly USA, LLC | 3 | $52 |
| Novo Nordisk Inc | 2 | $38 |
| Medtronic, Inc. | 2 | $35 |
| Dexcom, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $14 |
Products named: GVOKE HYPOPEN, MOUNJARO, Rybelsus, Dexcom G6 Transmitter, TRINTELLIX, REXULTI, ABRE, PULSESELECT.
Industry payments across MO — which companies pay providers there.
